PARIS and CAMBRIDGE, Mass., March 12, 2018 /PRNewswire/ --
Enterome SA, a clinical-stage biotech company pioneering innovative therapies to treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications, will present at the Cowen and Company 38th Annual Healthcare Conference on Wednesday 14 March from 11:00 to 11:25 AM (EDT).
The presentation will be held by Pierre Belichard, CEO of Enterome, and will include an overview of the company´s approach and strategy as well as an update on its development programs, including progress on its two lead drug candidates:
Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD) and cancer.
Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.
Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel and gastro-intestinal diseases; and Bristol-Myers Squibb in immuno-oncology.
Enterome also has a 50/50 joint venture with Nestlé Health Science, called Microbiome Diagnostics Partners, focused initially on the development of novel microbiome-based diagnostics for IBD and liver diseases.
The Company was established in 2012 in Paris (France) to develop the discoveries made by the INRA metagenomic platform, and is backed by leading venture capital investors (Seventure Partners, Lundbeckfonden Ventures, Health for Life Capital, Omnes Capital and Principia) and strategic investors (BMS, Nestlé Health Science, Shire & INRA Transfert).
Additional information about Enterome is available through its website: www.enterome.com
Contacts Pierre Belichard, CEO [email protected]
Media relations Mark Swallow / Marine Perrier / David Dible Citigate Dewe Rogerson Tel. +44-207-638-9571 [email protected] Investor relations Lisa Pavelka Rx Communications Group Tel. +1-917-843-0223 [email protected]
SOURCE Enterome
Advertisement
Enterome SA, a clinical-stage biotech company pioneering innovative therapies to treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications, will present at the Cowen and Company 38th Annual Healthcare Conference on Wednesday 14 March from 11:00 to 11:25 AM (EDT).
Advertisement
The presentation will be held by Pierre Belichard, CEO of Enterome, and will include an overview of the company´s approach and strategy as well as an update on its development programs, including progress on its two lead drug candidates:
- EB8018, a novel small molecule designed to block FimH in IBD, which is expected to start a Phase IIa clinical proof of concept trial in patients with Crohn's disease later this year; and
- EO2315/EO2401 in IO, a novel microbiome-derived cancer therapeutic vaccine expected to enter into Phase Ib study in 2018.
Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD) and cancer.
Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.
Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel and gastro-intestinal diseases; and Bristol-Myers Squibb in immuno-oncology.
Enterome also has a 50/50 joint venture with Nestlé Health Science, called Microbiome Diagnostics Partners, focused initially on the development of novel microbiome-based diagnostics for IBD and liver diseases.
The Company was established in 2012 in Paris (France) to develop the discoveries made by the INRA metagenomic platform, and is backed by leading venture capital investors (Seventure Partners, Lundbeckfonden Ventures, Health for Life Capital, Omnes Capital and Principia) and strategic investors (BMS, Nestlé Health Science, Shire & INRA Transfert).
Additional information about Enterome is available through its website: www.enterome.com
Contacts Pierre Belichard, CEO [email protected]
Media relations Mark Swallow / Marine Perrier / David Dible Citigate Dewe Rogerson Tel. +44-207-638-9571 [email protected] Investor relations Lisa Pavelka Rx Communications Group Tel. +1-917-843-0223 [email protected]
SOURCE Enterome
